Ms. Walker is a strategic C-suite executive and board director with 20+ years of experience providing compliance, corporate governance, regulatory, risk management, M&A, IP, and legal expertise for public and private biopharmaceutical and retail companies – Goldfinch Bio, Biogen (Nasdaq: BIIB), Stoke Therapeutics Inc. (Nasdaq: STOK) and Staples. As a trusted Management team leader, she advises boards and the C-suite on collaborations, licensing, IPOs, venture capital, healthcare, compliance, business development, executive compensation, U.S. securities laws, corporate communications, and investor relations. As Chief Legal Officer, Chief Compliance Officer & Corporate Secretary for the precision medicine company Goldfinch Bio, Inc., Ms. Walker provides corporate governance and advises the Board and Board Committees (Audit, Compensation, Nom/Gov) on clinical and business strategy.
Ms. Walker brings to public and high-growth company boards her expertise navigating from R&D through commercialization of ultra-rare to blockbuster products, creating post-IPO growth strategies – ensuring compliance and mitigating risk. She also is suited to advise companies examining financing opportunities; those transitioning from pre-clinical to clinical stage, and those preparing for IPO and other financings, ones considering expansion/commercialization, or companies needing to validate their own science who are exploring a larger collaboration partner. Robin asks insightful questions through a broad perspective. Ms. Walker serves on the Board of Directors of the Massachusetts General Hospital and Nuvara Therapeutics.